Skip to navigation Skip to content

Commercial Research Funding


Commercial R&D Funding

Through Fast Forward, we are making high-impact early-stage investments to accelerate commercial Research and Development for new therapies, diagnostics, and symptom management strategies for MS.

As a driving force of MS research to find pathways to a cure, the National MS Society takes a unique, comprehensive approach to funding research efforts. Since 2008 the National MS Society, through Fast Forward, has been driving the development of new therapies and diagnostics for people living with MS. Fast Forward  bridges the preclinical commercial funding gap, targets funds to de-risk therapeutic development and catalyzes further commercial investment.

2023 REQUEST FOR APPLICATIONS This RFA is now closed
Therapeutic Development Opportunities Addressing Nervous System Repair in Multiple Sclerosis

Fast Forward Application Instructions

Learn more about Fast Forward

For more information, please contact:

Mark Allegretta PhD    
Vice President, Research
Walter Kostich PhD    
Director, Commercial Research


© 2023 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.